We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fusion Antibodies Plc | FAB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.65 | -7.43% | 8.10 | 14:24:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.75 | 8.00 | 8.75 | 8.10 | 8.75 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 20/1/2025 16:35 by thiopia I don't think any Big Pharma will buy FAB. FAB is like the ARM of the semiconductor industry it has more value as an independent third party player selling into the arms race between the various biotechs/pharmas.Like ARM the long term value will be in the royalties/milestones they secure on IP/antibodies which eventually make it as therapeutics earning FAB a growing stream of income thanks to/leveraging the R&D and Sales & Marketing power of bios/Big Pharma |
Posted at 17/1/2025 18:47 by imjustdandy As we approach April many businesses are contemplating redundancies to cover increased national insurance costs thanks to this stupid Labour government. The NI costs are going to be a real challenge for business and will have a real knock on effect to staffing as well as reducing profits. It is hard to believe that FAB must be one of the few UK companies that have already mitigated this risk and NI cost which has been covered in their new £6m grant funding. FAB has not only mitigated NI costs on future hires, it has actually covered the full cost of 20 employees PA for the next 5 years. This gives the business confidence to take on larger contracts as the resource is already funded therefore profits will bet skewed significantly to the upside thanks to this 5 year Grant for £6m. It must be a great comfort to the CEO and FD knowing they can shoot the lights out on top line revenue and overheads won't increase as a result. Really well done to whoever neg this grant as its much more lucrative than the market has given them credit for. We are also waiting on updates on the following -Fusion Antibodies expanded its collaboration with the National Cancer Institute to include humanization services for existing camelid nanobodies. - They secured a new contract for an antibody-based therapeutic with an unnamed US-based biotechnology company. - They also undertook the development of a bespoke OptiPhage library for an unnamed client. When you consider the AI library / technology, Pharma partners like GSK etc, / new fixed overheads that allow the business to scale rapidly , No debt and a CEO stressing they working towards cashflow breakeven without a raise then FAB for me is an excellent buy in this sector especially when you consider other sectors that will need to deal with sever headwinds from this labour government. |
Posted at 13/1/2025 14:53 by thiopia Great spot above. I imagine the Companies interested in FAB will be multiples bigger than Charles River and will be prepared to pay multiples higher for FAB than Charles River have paid for the 'SuperHuman' Antibody companyThe US National Cancer Institute will play a big part in validating FAB platform and will determine what multiple of 100p we eventually see here. IMO. |
Posted at 13/1/2025 14:23 by imjustdandy Posted on LSE - Just confirms we are looking at a quid min for a FAB takeoverToday 13:37 Imagine the fab optiphage client decides they want that whole technology - could be around this value maybe - that was just to get access to one platform and fab have multiple ones |
Posted at 12/1/2025 13:40 by imjustdandy As we approach April many businesses are contemplating redundancies to cover increased national insurance costs thanks to this stupid Labour government. The NI costs are going to be a real challenge for business and will have a real knock on effect to staffing as well as reduced profits. It is hard to believe that FAB must be one of the few UK companies that have already mitigated this NI cost and associated risk which has been covered in their new £6m grant funding. FAB has not only mitigated NI costs on future hires, it has actually covered the full cost of 20 employees PA for the next 5 years. This gives the business confidence to take on larger contracts as the increased resources to deal with large contracts is already funded therefore profits will be significantly skewed to the upside thanks to this 5 year overhead Grant for £6m. It must be a great comfort to the CEO and FD knowing they can shoot the lights out on top line revenue and overheads won't increase as a result. Really well done to whoever neg this grant as its much more lucrative than the market has given them credit for. We are also waiting on updates on the following -Fusion Antibodies expanded its collaboration with the National Cancer Institute to include humanization services for existing camelid nanobodies. - They secured a new contract for an antibody-based therapeutic with an unnamed US-based biotechnology company. - They also undertook the development of a bespoke OptiPhage library for an unnamed client. When you consider the AI library / technology, Pharma partners like GSK etc, / new fixed overheads that allow the business to scale rapidly , No debt and a CEO stressing they are working towards cashflow breakeven without a raise then FAB for me is an excellent buy in this sector especially when you consider other sectors that will need to deal with severe headwinds from this labour government. |
Posted at 10/1/2025 07:35 by lfdkmp Post by trout over on LSE"Please stop replying to it, it has never heard of FAB before it was posted on the HVO thread the other day, as a NY tip from another poster there, not me. It is like a cancer (and yes I know first hand about cancer), so please just put on filter and stop feeding the tumour....." I suspect I am the culprit who posted about FAB on HVO thread. It was never my intention to encourage the stt contagion onto this FAB board or LSE (where I read but don't post). However, I am old enough and ugly enough that I should have been aware of the probability of such cross thread contagion and as such I offer an unreserved apology to posters here and over on LSE. FWIW, stt is one of the few posters that I have on permanent filter. |
Posted at 06/1/2025 23:10 by paulsavannah TLY looks good on paper but the difference between it and FAB is that the opportunities for FAB are endless or limitless whereas with TLY they are very dependent on Govt or NHS contracts and very susceptible to competitors. I'm not saying FAB isn't either but I believe FAB will be bought over in the short to medium term and at its current price its a sitting duck. |
Posted at 03/1/2025 07:35 by imjustdandy Fusion Antibodies (FAB): 7p Target 15pAfter some three years with its shares in the doghouse, made worse by the post pandemic hangover for biotechs, we have seen the FAB phoenix rise from the ashes. The driver in the recent past has been the prospect of what the stock market is very keen on, non-dilutive funding. In this instance, there is the prospect of approximately £1 million of direct funding for research & development initiatives, and access to up to £5 million of capital equipment. All of this coupled by the way that at the interim stage as reported in November FAB revenue had more than doubled, means that fans of the company are looking at a situation where 2025 could be a pivotal year. Before all the good news this autumn as recently as a year ago the shares were trading at 9p, and therefore one would expect this to be easily beaten in Q1 2025. |
Posted at 02/1/2025 22:02 by thiopia It's quite a bizarre claim.The main venues for ramping to the masses / great unwashed tends to Twitter or Telegram groups nowadays. There are hardly any posts on Twitter (the few who are promotional get zero to little engagement). I'm not aware of any Telegram group for FAB. As mentioned here there were hardly any posts on FAB on this thread this morning as it was moving. Part of the investment case for FAB that attracted me was the fact it was Unloved Underowned Undervalued as demonstrated by a long flat basing pattern in the share price. Not the sort of stock which appeals to rampers who love volatility. |
Posted at 17/12/2024 06:37 by lfdkmp Have just sent the following message to FAB - will be interesting to see if, and how quickly, the slides and presentations get amended."Having researched and witnessed FAB presentations I am excited by your prospects and am now a significant shareholder. At the risk of being considered pedantic, FAB is "certified" to ISO 9001, not "accredited" to ISO 9001. The people who are "accredited" are the certification bodies (eg BSI, Lloyds Registrar, NQA etc). I used to work for one of these. Some might consider the distinction to be a moot point, but given the nature of FAB operations and business environment, you would not want to be perceived by potential or existing clients as being imprecise or tolerant of lack of exactitude." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
